Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 83.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,600 shares of the specialty pharmaceutical company’s stock after buying an additional 3,000 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Jazz Pharmaceuticals were worth $1,248,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also recently modified their holdings of the business. Hilltop National Bank bought a new stake in shares of Jazz Pharmaceuticals during the 4th quarter valued at about $36,000. LRI Investments LLC bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth approximately $38,000. Danske Bank A S purchased a new stake in Jazz Pharmaceuticals in the third quarter valued at approximately $40,000. Geneos Wealth Management Inc. lifted its position in Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its position in Jazz Pharmaceuticals by 1,383.3% during the third quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 332 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.
Insider Activity at Jazz Pharmaceuticals
In other Jazz Pharmaceuticals news, Director Heather Ann Mcsharry sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $241.00, for a total value of $482,000.00. Following the completion of the sale, the director owned 18,449 shares in the company, valued at approximately $4,446,209. The trade was a 9.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $240.47, for a total value of $1,442,820.00. Following the sale, the director directly owned 366,682 shares of the company’s stock, valued at approximately $88,176,020.54. This trade represents a 1.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,098 shares of company stock worth $3,131,906 over the last three months. Corporate insiders own 4.10% of the company’s stock.
Jazz Pharmaceuticals Price Performance
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The firm had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%. Research analysts anticipate that Jazz Pharmaceuticals PLC will post 21.9 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several analysts have recently weighed in on JAZZ shares. Wells Fargo & Company raised their price objective on shares of Jazz Pharmaceuticals from $265.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday. Barclays increased their target price on Jazz Pharmaceuticals from $253.00 to $260.00 and gave the company an “overweight” rating in a research note on Tuesday. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $188.00 to $307.00 in a research note on Tuesday, May 19th. Deutsche Bank Aktiengesellschaft upped their price objective on Jazz Pharmaceuticals from $250.00 to $270.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Finally, Robert W. Baird set a $252.00 price objective on Jazz Pharmaceuticals in a report on Wednesday, May 6th. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $254.47.
Check Out Our Latest Analysis on Jazz Pharmaceuticals
Jazz Pharmaceuticals Profile
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.
Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.
Read More
- Five stocks we like better than Jazz Pharmaceuticals
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
